contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pharma-equity-group-opdatering-fra-interview-med-ceo-thomas-k-selso

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Pharma Equity Group

CEO Thomas K. Selsø opdatering fra selskabets netop aflagte Q3 regnskab

Pharma Equity Group er et investeringsselskab med fokus p&#xe5; Life Science sektoren og vigtiste aktiv er det 100% ejet datterselskab Reponex. Selskabet fokuserer p&#xe5; repositionering af allerede eksisterende l&#xe6;gemidler og har seks kandidater i fase 2. V&#xe6;rdiskabelsen ligger i fase 2 udviklingen af kandidaterne samt at finde de rette partnere til videreudvikling i fase 3. Pharma Equity Group&apos;s tre vigtigste kandidater med mulige partnere i 2025 er RNX-051 (Colorectal cancer &amp; Colon adnoma), RNX-41 (Inflammatory Bowels diseases) samt RNX-011 (Peritonitis). Efter kvartalets afslutning har RNX-051 f&#xe5;et godkendt sit patent i Japan og har allerede godkendelse i Europa, to af selskabets vigtigste markeder for kolorektal cancer. De afventer stadigv&#xe6;k godkendelse af deres patent i US.
Udover nyheder p&#xe5; pipelinen gennemgik CEO thomas K. Sels&#xf8; det finansielle beredskab og hvorfor selskabet iflg. regnskabsreglerne har nedsat den nominelle aktiekapital. Efterf&#xf8;lgende har selskabet lavet en rettet emission mod nye og eksistrende aktion&#xe6;rer med en pr&#xe6;mie til kursen dagen inden.
Hvad sker der med selskabets fordring i Portinho? i forbindelse med Pharma Equity Group&apos;&apos;s introduktion p&#xe5; b&#xf8;rsen havde selskabet gennemg&#xe5;et en &quot;Due Dilligence&quot; af denne fordring men betaling er stadigv&#xe6;k udebliven. CEO Thomas K Sels&#xf8; gav mere indblik i hvorfor det tr&#xe6;kker ud, og de g&#xf8;r alt hvad der st&#xe5;r i deres magt for at f&#xe5; afsluttet sagen.
&#xa0;
Disclaimer: HC Andersen Capital modtager betaling fra&#xa0; Pharma Equity Group for en Digital IR/Corporate Visibility abonnementsaftale. Analytiker Claus Thestrup 8:30 AM, 18.11.2024